title: [Myasthenia gravis--current treatment standards and emerging drugs].
abstract: Myasthenia gravis is very rare autoimmune disease of neuromuscular junction, which presents as a weakness and increased fatiquability of striated muscles. Formerly, myasthenia was largely constraining disease and often ended by death. Recently, advanced diagnostic methods and variety of therapeutic options allow the full compensation of the disease and the quality of patient life is restored. In this review, the methods used during the myasthenia treatment along with the description of the disease itself were detailed.
authors.affiliation: Univerzita Karlova v Praze, Farmaceutická fakulta Hradec Králové, Katedra farmaceutické chemie a kontroly léciv.
authors.forename: Komlóová
authors.initials: K
authors.lastname: Markéta
authors.forename: Musílek
authors.initials: M
authors.lastname: Kamil
authors.forename: Kuca
authors.initials: K
authors.lastname: Kamil
mesh_terms: D000110:Acetylcholinesterase / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000110:Acetylcholinesterase